Malignant Abnormalities in Male BRCA Mutation Carriers

There were no differences between arms among the secondary outcomes (Table ).There were 18 serious adverse events: 8 in patients receiving ketamine and 10 in patients receiving placebo.Common adverse events were cognitive disturbance, dizziness, fatigue, nausea, and somnolence.Discussion | This trial reports that ketamine was equivalent to placebo for cancer-related neuropathic pain.Findings enhance previous work 4 by examining ketamine in cancerrelated neuropathic pain.There may be subgroups of patients for whom ketamine is helpful, such as those with central sensitization.A limitation of the present study was that we did not specifically select patients with clinical evidence of central sensitization, for whom it is reasonable to hypothesize a more specific analgesic target for ketamine.Future studies that examine ketamine in chronic neuropathic pain should focus on patients with central sensitization, which can be established by a bedside test.This approach would be congruent with preclinical knowledge and would address an important remaining unanswered question.